(Total Views: 479)
Posted On: 01/01/2020 11:11:42 PM
Post# of 154119
Re: crazyjogger925 #14086
It would depend in how many indications leronlimab works and whether we commercialize alone or what deals we can make.
If leronlimab works in all of most likely indications - Before the current deal was announced, based on 700m shares, our own commercialization in U.S. and waiting out overseas deals for optimal return (40% net sales) I cranked out a fast and loose $300 per share. With HIV off the table, maybe $260 per share. If we set deals for other indications, share price will be determined by the terms of the deals.
If leronlimab works in all of most likely indications - Before the current deal was announced, based on 700m shares, our own commercialization in U.S. and waiting out overseas deals for optimal return (40% net sales) I cranked out a fast and loose $300 per share. With HIV off the table, maybe $260 per share. If we set deals for other indications, share price will be determined by the terms of the deals.
(1)
(0)
